IRME · As filed with the SEC
IR-Med income statement, by fiscal year
The statement as IR-Med presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 |
|---|---|---|
| Research and development expenses | ||
| Expenses incurred | 1,178 | 2,061 |
| Less- government grants | (468) | — |
| Research and development expenses, net | 710 | 2,061 |
| Marketing Expense | 220 | 822 |
| Selling, General and Administrative Expense | 1,011 | 2,028 |
| Total operating loss | 1,941 | 4,911 |
| Other income | (48) | — |
| Financial expenses (income), net | 6 | (2) |
| Loss for the year | 1,899 | 4,909 |
| Earnings Per Share (Basic) | (0.03) | (0.07) |
| Earnings Per Share (Diluted) | (0.03) | (0.07) |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.